Generate a tailored SOP for Dr. Michael Morse. Improve your application with a focused, well-structured draft.
Michael Aaron Morse is a distinguished Professor of Medicine in the Department of Surgery at Duke University and a member of the Duke Cancer Institute. His research focuses on the use of immune therapies to treat various types of cancers including gastrointestinal, breast, lung cancers, and melanoma. The therapies developed in his lab include dendritic cell-based vaccines, peptide vaccines, viral vectors, and DNA plasmids. He is recognized nationally for his leadership in developing laboratory assays that demonstrate immunologic responses to cancer vaccines. Currently, his group is also developing immunotherapies that incorporate adoptive transfer of tumor antigen-specific T cells. Clinical trials under his guidance include Phase II studies of immunotherapy for patients with metastatic malignancies that express Carcinoembryonic Antigen (CEA), as well as investigations into pancreatic, colorectal, breast, ovarian cancers, and leukemias. His clinical expertise lies specifically in gastrointestinal oncology, with a particular focus on the treatment of hepatic malignancies and malignant melanoma.
Department of Biomedical Engineering (MS program)